FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis

FDA News, New FDA Approvals
September 20, 2021
A+ A-
Email Print

Article Link: FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis

INCHEON, Korea and CAMBRIDGE, Mass. – September 20, 2021 – Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar…

Source: FDA New Drug Approvals

Newer Post
Older Post